2269 related articles for article (PubMed ID: 19432355)
21. Changes in the size and number of skin lesions in PB leprosy on treatment and follow-up.
Rao PN; Suneetha S; Pratap DV
Lepr Rev; 2011 Sep; 82(3):244-52. PubMed ID: 22125932
[TBL] [Abstract][Full Text] [Related]
22. A study on the impact of FD-MDT on 200 leprosy patients.
Vara N; Marfatiya Y
Indian J Lepr; 2005; 77(3):217-27. PubMed ID: 16353520
[TBL] [Abstract][Full Text] [Related]
23. Incidence of late lepra reaction among multibacillary leprosy patients after MDT.
Vijayakumaran P; Manimozhi N; Jesudasan K
Int J Lepr Other Mycobact Dis; 1995 Mar; 63(1):18-22. PubMed ID: 7730714
[TBL] [Abstract][Full Text] [Related]
24. A study on trend of relapse in leprosy and factors influencing relapse.
Ali MK; Thorat DM; Subramanian M; Parthasarathy G; Selvaraj U; Prabhakar V
Indian J Lepr; 2005; 77(2):105-15. PubMed ID: 16044808
[TBL] [Abstract][Full Text] [Related]
25. A study on the effectiveness and safety of the WHO/MDT regimen in the northeast of Thailand; a prospective study, 1984-1996.
Dasananjali K; Schreuder PA; Pirayavaraporn C
Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):28-36. PubMed ID: 9207751
[TBL] [Abstract][Full Text] [Related]
26. Response of leprosy patients with single lesions to MDT.
Katoch K; Natrajan M; Yadav VS; Bhatia AS
Acta Leprol; 1995; 9(3):133-7. PubMed ID: 7631584
[TBL] [Abstract][Full Text] [Related]
27. Immunotherapy of far-advanced lepromatous leprosy patients with low-dose convit vaccine along with multidrug therapy (Calcutta trial).
Majumder V; Mukerjee A; Hajra SK; Saha B; Saha K
Int J Lepr Other Mycobact Dis; 1996 Mar; 64(1):26-36. PubMed ID: 8627110
[TBL] [Abstract][Full Text] [Related]
28. Ocular complications in incident relapsed borderline lepromatous and lepromatous leprosy patients in south India.
Daniel E; Koshy S; Joseph GA; Rao PS
Indian J Ophthalmol; 2003 Jun; 51(2):155-9. PubMed ID: 12831146
[TBL] [Abstract][Full Text] [Related]
29. Childhood leprosy in a tertiary-care hospital in Delhi, India: a reappraisal in the post-elimination era.
Singal A; Sonthalia S; Pandhi D
Lepr Rev; 2011 Sep; 82(3):259-69. PubMed ID: 22125934
[TBL] [Abstract][Full Text] [Related]
30. Clinical and histopathological correlation in the classification of leprosy.
Bhatia AS; Katoch K; Narayanan RB; Ramu G; Mukherjee A; Lavania RK
Int J Lepr Other Mycobact Dis; 1993 Sep; 61(3):433-8. PubMed ID: 8228443
[TBL] [Abstract][Full Text] [Related]
31. BCG immunotherapy as an adjunct to chemotherapy in BL-lL patients--its effect on clinical regression, reaction severity, nerve function, lepromin conversion, bacterial/antigen clearance and 'persister' M. leprae.
Shetty VP; Mistry NF; Wakade AV; Ghate SD; Capadia GD; Pai VV
Lepr Rev; 2013 Mar; 84(1):23-40. PubMed ID: 23741880
[TBL] [Abstract][Full Text] [Related]
32. Twenty five years follow up of MB leprosy patients retreated with a modified MDT regimen after a full course of dapsone mono-therapy.
Jing Z; Zhang R; Zhou D; Chen J
Lepr Rev; 2009 Jun; 80(2):170-6. PubMed ID: 19743621
[TBL] [Abstract][Full Text] [Related]
33. Experience with WHO-recommended multidrug therapy (MDT) for multibacillary (MB) leprosy patients in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center in Ethiopia: appraisal of the recommended duration of MDT for MB patients.
Becx-Bleumink M
Int J Lepr Other Mycobact Dis; 1991 Dec; 59(4):558-68. PubMed ID: 1802938
[TBL] [Abstract][Full Text] [Related]
34. The occurrence of reactions and impairments in leprosy: experience in the leprosy control program of three provinces in northeastern Thailand, 1987-1995 [correction of 1978-1995]. I. Overview of the study.
Schreuder PA
Int J Lepr Other Mycobact Dis; 1998 Jun; 66(2):149-58. PubMed ID: 9728447
[TBL] [Abstract][Full Text] [Related]
35. Treatment of bacilliferous BL/LL cases with combined chemotherapy and immunotherapy.
Katoch K; Katoch VM; Natrajan M; Bhatia AS; Sreevatsa ; Gupta UD; Sharma VD; Shivannavar CT; Patil MA; Bharadwaj VP
Int J Lepr Other Mycobact Dis; 1995 Jun; 63(2):202-12. PubMed ID: 7602215
[TBL] [Abstract][Full Text] [Related]
36. Effect of HIV infection on leprosy: a three-year survey in Bamako, Mali.
Lienhardt C; Kamate B; Jamet P; Tounkara A; Faye OC; Sow SO; Bobin P
Int J Lepr Other Mycobact Dis; 1996 Dec; 64(4):383-91. PubMed ID: 9030103
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of single-dose ROM therapy plus low-dose convit vaccine as an adjuvant for treatment of paucibacillary leprosy patients with a single skin lesion.
Majumder V; Saha B; Hajra SK; Biswas SK; Saha K
Int J Lepr Other Mycobact Dis; 2000 Sep; 68(3):283-90. PubMed ID: 11221091
[TBL] [Abstract][Full Text] [Related]
38. Field trial on efficacy of supervised monthly dose of 600 mg rifampin, 400 mg ofloxacin and 100 mg minocycline for the treatment of leprosy; first results.
Mane I; Cartel JL; Grosset JH
Int J Lepr Other Mycobact Dis; 1997 Jun; 65(2):224-9. PubMed ID: 9251595
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of a new fixed duration (12 weeks) multi-drug regimen of bactericidal drugs in multibacillary leprosy.
Tejasvi T; Khaitan BK; Khanna N; Pandhi RK; Singh MK
Indian J Lepr; 2006; 78(4):329-37. PubMed ID: 17402345
[TBL] [Abstract][Full Text] [Related]
40. 10-12 years follow-up of highly bacillated BL/LL leprosy patients on combined chemotherapy and immunotherapy.
Katoch K; Katoch VM; Natrajan M; Sreevatsa ; Gupta UD; Sharma VD; Shivanavar CT
Vaccine; 2004 Sep; 22(27-28):3649-57. PubMed ID: 15315844
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
